Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 289

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 289
---
 distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of Tisseel the 10 ml Tisseel kits per year at a fixed purchase price of $0.136 per unit. The payments under the Supply Agreement are due 30 days from the date of invoice and the Company is subject to a service charge of 1% per month on all amounts past due. |

The Supply Agreement had an initial
term of 3 years which ended on April 1, 2011; however, the Supply Agreement has an ever-green clause and is automatically renewable
for consecutive 1 year terms unless either party gives notice of termination at least 3 months prior to the then current term. The
Supply Agreement may be terminated without cause by Baxter upon 90 days’ prior written notice to the other parties. In
addition, either party may terminate the Supply Agreement in the event of an uncured material breach or insolvency.

<div align='center'>F-37</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

| 4. | In March 2019, the Company participated in the Horizon 2020 Research                                                                          
 and Innovation Framework Programme from European Union through the EASME for its participation in research and development activities         
 of the Company. Pursuant to the participation in the Programme, the EASME will fund R&D expenses up to total approved budget of approximately 
 $2,680 (EURO 2,185 thousand), out of which $1,095 (EURO 983 thousand) was received in 2019 and $1,039 (EURO 874 thousand) was received        
 in 2021. As of December 31, 2023, the Company, recorded the amount received as a grant liability in other accounts payable in balance         
 sheets (refer to Note 4). The grant liability will be recorded as reduction in research and development expenses once the Company receives    
 approval of the project completion. Considering the grantor’s entitlement to demand a complete reimbursement of the entire grant,